CMS gives thumbs-up to PET/Alzheimer’s coverage
This article was originally published in The Gray Sheet
Executive Summary
Final decision memo aligns with draft decision to cover the scans in a practical clinical trial and for differentiating between Alzheimer's disease and fronto-temporal dementia in patients that have been evaluated for other causes of dementia and still have uncertain clinical symptoms (1"The Gray Sheet" June 24, 2004, p. 6). The national coverage decision is the first reviewed under Medicare Modernization Act requirements for a draft decision posting followed by a 30-day comment period, and implementation of a final policy within 90 days of posting a final decision memo...
You may also be interested in...
Medicare Will Cover PET To Distinguish Alzheimer’s From Other Dementia
CMS' decision to provide national coverage of FDG-PET imaging for some suspected dementia patients corresponds with the Neuroimaging Work Group of the Alzheimer's Association's consensus position
Fujifilm Demonstrates Health Specialism With European HealthTech Spinout
From X-ray film in 1936 to the world’s first digital X-ray system in 1983, Fujifilm has a long heritage in medical diagnostics.
Financing Quarterly Statistics, Q1 2024
During Q1, biopharmas brought in an aggregate $30.1bn in financing and device company fundraising totaled $2.8bn; while in vitro diagnostic firms and research tools players raised $724m.